| Website | hcven.com |
| Phone | 617.252.4343 |
| Employees | |
| Description | Venture capital Firm |
HealthCare Ventures is a leading venture capital firm specializing in life science industry investing. At HealthCare Ventures we concentrate our investment dollars on life science companies showing high growth potential. Since 1985, we have maintained a constant objective to support entrepreneurs and to generate above average returns for our limited partners.
| Company | Date | Round | Size | Participants |
| Radius Health | 2/12 | Series C | $21.4M | 7 |
| Mosaic Biosciences | 11/11 | Series A | $1M | 3 |
| Sensors for Medicine and Science | 11/11 | Series D | $54.1M | 5 |
| Pathogenetix | 11/11 | Series B | $7.5M | 4 |
| Tensha Therapeutics | 9/11 | Series A | $15M | 1 |
| Cleveland HeartLab | 8/11 | Series B | $18.4M | 2 |
| Pathogenetix | 8/11 | Series B | $4M | 3 |
| Radius Health | 7/11 | Series C | $66M | 7 |
| nanoMR | 7/11 | Series B | $13M | 4 |
| CellNovo | 2/11 | Series B | £30M | 8 |
| Dicerna Pharmaceuticals | 10/10 | Series B | $4M | 2 |
| DecImmune Therapeutics | 9/10 | Unattributed | $3.2M | 3 |
| Anchor Therapeutics | 8/10 | Series B | $10M | 3 |
| TetraLogic Pharmaceuticals | 8/10 | Series C | $32M | 8 |
| Stemgent | 7/10 | Series B | $5.6M | 2 |
| Trevena | 7/10 | Series B | $35M | 4 |
| Foldrx Pharmaceuticals | 6/10 | Unattributed | $29M | 7 |
| Theraclone Sciences | 3/10 | Unattributed | $1.5M | 6 |
| Seahorse Bioscience | 3/10 | Series D | $5M | 7 |
| Stemgent | 11/09 | Debt | $2.7M | 2 |
| PharmAthene | 7/09 | Unattributed | $19.3M | 4 |
| Xanodyne | 6/09 | Series D | $38M | 7 |
| VaxInnate | 6/09 | Series D | $30M | 7 |
| Seahorse Bioscience | 3/09 | Series D | $6M | 7 |
| Catalyst Biosciences | 12/08 | Series C | $40M | 7 |
| Radius Health | 11/08 | Series C | $15M | 6 |
| Proteostasis Therapeutics | 8/08 | Series A | $45M | 5 |
| Trevena | 3/08 | Series A | $24M | 4 |
| Ascent Therapeutics | 11/07 | Series A | $8M | 3 |
| Radius Health | 4/07 | Series B | $57.5M | 6 |
| Sequoia Pharmaceuticals | 1/07 | Series C | $35M | 5 |
| VaxInnate | 10/06 | Series C | $40M | 6 |
| Promedior | 5/06 | Series A | $14M | 5 |
| Avidia | 5/06 | Series C | $43.8M | 7 |
| Catalyst Biosciences | 2/06 | Series B | $30M | 6 |
| Sequoia Pharmaceuticals | 3/05 | Series B | $22M | 4 |